Organovo (ONVO) said Tuesday that it has completed the sale of its farnesoid X receptor, or FXR, program to Eli Lilly (LLY).
The agreement was announced in February, with Organovo saying it will sell the FXR program for an upfront payment of $10 million and potential milestone payments of up to $50 million.
Eli Lilly has now acquired all commercial and intellectual property rights to the FXR program and will be responsible for its future clinical development.
Price: 2.92, Change: -0.07, Percent Change: -2.34
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。